- Oops!Something went wrong.Please try again later.
PALO ALTO, Calif. (AP) _ Eiger BioPharmaceuticals Inc. (EIGR) on Thursday reported a loss of $16.5 million in its fourth quarter.
On a per-share basis, the Palo Alto, California-based company said it had a loss of 92 cents.
The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 83 cents per share.
For the year, the company reported that its loss widened to $52.4 million, or $3.82 per share.
Eiger BioPharma shares have climbed 31 percent since the beginning of the year. In the final minutes of trading on Thursday, shares hit $13.31, a climb of 40 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on EIGR at https://www.zacks.com/ap/EIGR